Our trustees

In 2021, Matthew Wilson was diagnosed with multiple myeloma, a type of blood cancer. Following treatment he stepped down as CEO of Brit Insurance and later that year founded the Matthew Wilson Multiple Myeloma Fund for our charity.

Matthew is an advocate for all blood cancers and became our chair in early 2024 after an independent and robust recruitment process. He brings extensive leadership experience from his 35 year career in the insurance sector, where he was Chairman of Ki Insurance, as well as serving on the boards of Brit Limited, Brit Syndicates Limited, and Ki Financial.

Jules has worked across a range of causes in health, education and young people’s services. In 2002, Jules was diagnosed with Hodgkin Lymphoma. After several cycles of treatment, remission and relapse, she had a stem cell transplant in 2007 and is now considered cured.

As a result of his diagnosis, Ally established a partnership between the Fire and Rescue Service and the charity Anthony Nolan, which educates young people about stem cell, blood and organ donation and recruits them onto the stem cell register.

He is passionate about Patient and Public Involvement and provides input to several charities, research studies and committees. He is a Non-Executive Director of Scotland’s third largest NHS Board, NHS Lanarkshire, and was awarded an MBE in the 2018 Queen’s Birthday Honours for services to charity.

Most recently Tim spent 13 years at Columbia Threadneedle Investments, initially as Chief Financial Officer, then Chief Operating Officer and finally as interim Chief Executive Officer. Tim is also Director of TR Property Investment Trust PLC and of Henderson Global Investors Limited.

In March 2020, she co-founded CoronaUnity (now One Consulting), a non-profit organisation providing pro-bono consultancy services to third sector organisations. Jasmine was Head of Operations for the team for 6 months before taking on an advisory role.

Christine is a Fellow of the Academy of Medical Sciences. She has been a Researcher and Ambassador of Blood Cancer UK for the last 30 years, leading international projects towards improving therapy, particularly for children with leukaemia.

The focus of her clinical work is myeloproliferative neoplasms (MPN), for which she has a national and international reputation. Her clinical trial work has led to the approval of new therapies such a ruxolitinib, fedratinib and pacritinib and new experimental findings in this field. In the past ten years she has published over 250 academic articles.

Claire has a strong interest in patient advocacy and founded the UK MPN group. Under her leadership, the clinical MPN service at Guy's and St Thomas has become internationally recognised as a centre of excellence.

Inspired by youth volunteering and the desire to have a positive impact in her profession, Louise has worked both on the charity and agency side. Louise is Transformation Director at Manifesto, helping transform not-for-profit organisations; from their culture and organisational design to their technology and digital capabilities to drive sustainable change.

She has a wealth of experience working across UK and International Charity programmes at a strategic level spanning a multitude of areas including strategy, fundraising, brand, innovation, advocacy and campaigning. Alongside this, she is a professional mentor and founded a global mentoring community to support women in the social good space.

Claude acquired and later floated Powerleague plc, was Chairman of ASCO plc and deputy chairman of Blacks Leisure plc.

Claude is a long-time business associate of Lord Sugar, and has served as chairman of a number of his companies. Claude came to prominence as the tough interviewer on BBC 1's ‘The Apprentice’, as well as sitting alongside Karren Brady, as Lord Sugar’s ‘eyes and ears’ on the show. He also served as Chief Executive of Tottenham Hotspur plc when Lord Sugar was Chairman.

In 2014, the University of West London renamed the business school ‘The Claude Littner Business School’ in appreciation of his business success and contribution to the University. He is a Visiting Professor at the University.

Steve then became a Regional Chair for Blood Cancer UK and in November 2017 joined the Board. Steve has spent the last two decades working in technology for organisations such as EDS, HP and Fujitsu. He is Head of Infrastructure and Shared Services at Imperial College.

Steve still fundraises with his local branch and has cycled London to Paris, Ride London, along with coast to coast rides for Blood Cancer UK and is the Trustee representative for our Public Fundraising portfolio.

Amir is a sustainability expert and change agent. Coming from a Big 4 consulting background, he has a track record in designing and implementing innovative, commercial and sustainable solutions. Amir joined MS Amlin in 2021, into a newly created role, signalling the business’s investment in ESG. Under his leadership, MS Amlin has committed to net zero 2050 and focused on fair and inclusive transition that reflects the needs of MS Amlin’s clients, shareholder, employees and communities.

Amir led the development of MS Amlin’s new Sustainability Strategy, which supports a commitment to create long term enterprise value by doing the right thing. Prior to joining MS Amlin, he led a sustainable finance start-up and was formerly a Director at KPMG. He is a qualified Chartered Accountant.

Fraser works with financial services clients across the UK and leads PwC’s financial services practice in Scotland, where he is based. He has a deep personal connection with the charity having lost a close family member to leukaemia and has previously fundraised for Blood Cancer UK.